{"Clinical Trial ID": "NCT02006979", "Intervention": ["INTERVENTION 1:", "Financial year", "One acute exercise session was conducted 24 hours before each cycle of anthracyclines and no exercise for 48 hours after exercise.", "INTERVENTION 2:", "Usual care", "No exercise for 72 hours before or 48 hours after each cycle of anthracyclines"], "Eligibility": ["Incorporation criteria:", "New breast cancer diagnosis at stage I-IIIA", "Doxorubicin neoadjuvant or adjuvant chemotherapy is expected in cycles of 2-3 weeks.", "Receive approval from their oncologist for the exercise", "To be able to complete the first point of data collection before the first cycle of chemotherapy", "Be able to understand and provide informed consent in writing in English", "- Exclusion criteria:", "\u2022 Simultaneous participation in a program or study of structured exercises", "Orthopaedic restrictions on exercise", "\u2022 Pre-existing cardiovascular disease", "Uncontrolled hypertension (blood pressure 140/90 mmHg)", "- Uncontrolled diabetes", "Respiratory disorders", "Current smoking situation"], "Results": ["Performance measures:", "Global Longitudinal Detachment", "Enjoyed with 2D Spic follow-up echocardiography", "Duration: 24-48 hours after the first doxorubicin and 7-14 days after the end of the last doxorubicin cycle", "Results 1:", "Title of arm/group: Exercise", "- Arm/group description: an acute exercise 24 hours before each cycle of anthracyclines and no exercise for 48 hours after exercise", "Total number of participants analysed: 13", "Average (standard deviation)", "Unit of measurement: per cent deformation Reference: 19.2 (1.9)", "24-48 h after first doxorubicin: 21.4 (1.8)", "7-14 days after last doxorubicin: -18.7 (1.4)", "Results 2:", "Title of arm/group: Usual care", "Description of the arm/group: no exercise for 72 hours before or 48 hours after each cycle of anthracyclines", "Total number of participants analysed: 11", "Average (standard deviation)", "Unit of measurement: % deformation Reference: -19.6 (1.9)", "24-48 h after first doxorubicin: -21.5 (1.6)", "7-14 days after last doxorubicin: -20.3 (1.6)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/13 (0.00 per cent)", "Adverse Events 2:", "Total: 0/11 (0.00 per cent)"]}